Investor Presentaiton

Robust Pipeline Across Novel Therapeutics 4 commercialized assets, 5 assets in pivotal trials and 14 assets in clinical stage Status Products Target (s) Therapeutic Area Commercial Rights Pre-clinical IND Approved Phase 1 Phase 2 Pivotal Phase 2/ Phase 3 NDA Launched Lilly TYVYT (sintilimab injection) PD-1 Oncology Worldwide BYVASDA (bevacizumab injection) VEGF-A Oncology Worldwide SULINNOⓇ (adalimumab injection) TNF-alpha Autoimmune Lilly HALPRYZA (rituximab injection) CD20 Oncology Worldwide Worldwide 2L MCCA (pivotal Phase 2 in mainland China); 2L mCCA (NDA accepted in Taiwan market) Incyte IBI-375 (Pemigatinib) FGFR1/2/3 Oncology Mainland China, HK, Taiwan, Macau 1L CCA (joined Incyte's global Phase 3 trial) HOFH (China) IBI-306 PCSK9 Metabolic Mainland China, HK, Taiwan, Macau HeFH (China) Worldwide IBI-310 CTLA-4 Oncology Incyte IBI-376 (Parsaclisib) РІЗКО Oncology Mainland China, HK, Taiwan, Macau IBI-326 BCMA-CART Oncology Worldwide Lilly IBI-362 OXM3 Metabolic IBI-188 Lilly IBI-318 CD47 Oncology PD-1/PD-L1 Mainland China, HK, Taiwan, Macau Worldwide Oncology Mainland China, HK, Macau nFH (China) Adjuvant melanoma (China) 1L HCC (China) 2L cervical cancer (China) r/r FL and MZL (China) Myelofibrosis (Incyte's global Phase 3) r/r MM (China) Obesity (China) Diabetes (China) MDS (China) MDS (US) r/r AML (China) SCLC (China) NK/T-cell lymphoma (China) CSCC (China) Neo-adjuvant/adjuvant HCC (China) WAMD (China) IBI-302 IBI-110 Hanmi IBI-315 VEGF/Complement proteins Ophthalmology Worldwide IBI-939 LAG-3 PD-1/HER2 TIGIT Oncology Worldwide Advanced malignancies (China) Oncology Worldwide Advanced malignancies (China) Oncology Worldwide Advanced malignancies (China) IND approved (US) IBI-322 PD-L1/CD47 Oncology Worldwide IBI-112 IL-23 p19 Autoimmune Worldwide Advanced malignancies (China) Advanced malignancies (US) Inflammatory enteritis and other autoimmune diseases (China) IBI-101 OX40 Oncology Worldwide Solid tumor (China) IBI-323 LAG-3/PD-L1 Oncology Worldwide IND approved (China) IBI-102 GITR Oncology Worldwide IND approved (China) Lilly Lilly IBI-321 IBI-319 PD-1/4-1BB Oncology Mainland China, HK, Macau IND approved (China) PD-1/TIGIT Oncology Mainland China, HK, Macau IND accepted (China) Listed drugs Biologics Small molecules Clinical progress in the U.S. Innovent Confidential Copyright©2021 Innovent Biologics 14

View entire presentation